PB1938: 4WHIM: EVALUATING MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, IN PATIENTS WITH WHIM SYNDROME VIA A GLOBAL PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH OPEN-LABEL EXTENSION
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000850592.82147.9b |
| _version_ | 1827336972547391488 |
|---|---|
| author | D. C. Dale L. Alsina A. Azar R. Badolato Y. Bertrand A. Deya K. E. Dickerson N. Ezra H. Hasle H. J. Kang S. Kiani-Alikhan T. Kuijpers A. Kulagin D. Langguth C. Levin O. Neth J. Peake C. E. Rutten A. Shcherbina T. K. Tarrant M. G. Vossen C. A. Wysocki A. Belschner D. Cadavid Y. Hu H. Jiang R. MacLeod W. Tang M. Tillinger J. Donadieu |
| author_facet | D. C. Dale L. Alsina A. Azar R. Badolato Y. Bertrand A. Deya K. E. Dickerson N. Ezra H. Hasle H. J. Kang S. Kiani-Alikhan T. Kuijpers A. Kulagin D. Langguth C. Levin O. Neth J. Peake C. E. Rutten A. Shcherbina T. K. Tarrant M. G. Vossen C. A. Wysocki A. Belschner D. Cadavid Y. Hu H. Jiang R. MacLeod W. Tang M. Tillinger J. Donadieu |
| author_sort | D. C. Dale |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:43:12Z |
| format | Article |
| id | doaj.art-2d8f9dddd1444c099d979b8d305847f6 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:43:12Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-2d8f9dddd1444c099d979b8d305847f62024-03-02T03:29:00ZengWileyHemaSphere2572-92412022-06-0161814181510.1097/01.HS9.0000850592.82147.9b202206003-01814PB1938: 4WHIM: EVALUATING MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, IN PATIENTS WITH WHIM SYNDROME VIA A GLOBAL PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH OPEN-LABEL EXTENSIOND. C. Dale0L. Alsina1A. Azar2R. Badolato3Y. Bertrand4A. Deya5K. E. Dickerson6N. Ezra7H. Hasle8H. J. Kang9S. Kiani-Alikhan10T. Kuijpers11A. Kulagin12D. Langguth13C. Levin14O. Neth15J. Peake16C. E. Rutten17A. Shcherbina18T. K. Tarrant19M. G. Vossen20C. A. Wysocki21A. Belschner22D. Cadavid23Y. Hu24H. Jiang25R. MacLeod26W. Tang27M. Tillinger28J. Donadieu291 Department of Medicine, University of Washington, Seattle, United States of America2 Allergy and Clinical Immunology Department, Hospital Sant Joan de Déu Barcelona, Institut de Recerca Sant Joan de Déu, Barcelona, Spain3 Division of Allergy and Clinical Immunology, Johns Hopkins University, Baltimore, United States of America4 Department of Pediatrics, Angelo Nocivelli Institute of Molecular Medicine, University of Brescia, Brescia, Italy5 Institute of Pediatric Hematology and Oncology (IHOPe), Civil Hospital of Lyon, Lyon, France2 Allergy and Clinical Immunology Department, Hospital Sant Joan de Déu Barcelona, Institut de Recerca Sant Joan de Déu, Barcelona, Spain6 Department of Pediatrics, Division of Hematology and Oncology, UT Southwestern Medical Center, Dallas7 California Dermatology Institute, Thousand Oaks, United States of America8 Department of Paediatrics, Aarhus University Hospital, Aarhus, Denmark9 Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Cancer Research Institute, Wide River Institute of Immunology, Seoul National University Children’s Hospital, Seoul, South Korea10 Department of Immunology, Barts Health NHS Trust, London, United Kingdom11 Department of Paediatric Immunology, Rheumatology and Infectious Diseases, Amsterdam University Medical Center, Amsterdam, Netherlands12 RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russia13 Immunology Department, Sullivan Nicolaides Pathology Auchenflower, Queensland, Australia14 Pediatric Hematology Unit, Emek Medical Center, Afula and the Ruth and Bruce Rappaport Faculty of Medicine Technion, Haifa, Israel15 Pediatric, Infectious Diseases, Rheumatology and Immunology Department, Hospital Virgen del Rocío, Institute of Biomedicine of Seville (IBIS), Seville, Spain16 Department of Allergy and Immunology, Queensland Children’s Hospital, University of Queensland, South Brisbane, Queensland, Australia17 Department of Hematology, Amsterdam University Medical Center, Amsterdam, Netherlands18 Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia19 Division of Rheumatology and Immunology, Department of Medicine, Duke University, Durham, United States of America20 Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Medical University of Vienna, Vienna, Austria21 Division of Allergy and Immunology, Departments of Pediatrics and Internal Medicine, UT Southwestern Medical Center, Dallas22 X4 Pharmaceuticals, Boston, United States of America22 X4 Pharmaceuticals, Boston, United States of America22 X4 Pharmaceuticals, Boston, United States of America22 X4 Pharmaceuticals, Boston, United States of America22 X4 Pharmaceuticals, Boston, United States of America22 X4 Pharmaceuticals, Boston, United States of America22 X4 Pharmaceuticals, Boston, United States of America23 Service d’Hémato-Oncologie Pédiatrique, Hôpital Trousseau, Paris, Francehttp://journals.lww.com/10.1097/01.HS9.0000850592.82147.9b |
| spellingShingle | D. C. Dale L. Alsina A. Azar R. Badolato Y. Bertrand A. Deya K. E. Dickerson N. Ezra H. Hasle H. J. Kang S. Kiani-Alikhan T. Kuijpers A. Kulagin D. Langguth C. Levin O. Neth J. Peake C. E. Rutten A. Shcherbina T. K. Tarrant M. G. Vossen C. A. Wysocki A. Belschner D. Cadavid Y. Hu H. Jiang R. MacLeod W. Tang M. Tillinger J. Donadieu PB1938: 4WHIM: EVALUATING MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, IN PATIENTS WITH WHIM SYNDROME VIA A GLOBAL PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH OPEN-LABEL EXTENSION HemaSphere |
| title | PB1938: 4WHIM: EVALUATING MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, IN PATIENTS WITH WHIM SYNDROME VIA A GLOBAL PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH OPEN-LABEL EXTENSION |
| title_full | PB1938: 4WHIM: EVALUATING MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, IN PATIENTS WITH WHIM SYNDROME VIA A GLOBAL PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH OPEN-LABEL EXTENSION |
| title_fullStr | PB1938: 4WHIM: EVALUATING MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, IN PATIENTS WITH WHIM SYNDROME VIA A GLOBAL PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH OPEN-LABEL EXTENSION |
| title_full_unstemmed | PB1938: 4WHIM: EVALUATING MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, IN PATIENTS WITH WHIM SYNDROME VIA A GLOBAL PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH OPEN-LABEL EXTENSION |
| title_short | PB1938: 4WHIM: EVALUATING MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, IN PATIENTS WITH WHIM SYNDROME VIA A GLOBAL PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH OPEN-LABEL EXTENSION |
| title_sort | pb1938 4whim evaluating mavorixafor an oral cxcr4 antagonist in patients with whim syndrome via a global phase 3 randomized placebo controlled trial with open label extension |
| url | http://journals.lww.com/10.1097/01.HS9.0000850592.82147.9b |
| work_keys_str_mv | AT dcdale pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT lalsina pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT aazar pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT rbadolato pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT ybertrand pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT adeya pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT kedickerson pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT nezra pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT hhasle pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT hjkang pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT skianialikhan pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT tkuijpers pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT akulagin pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT dlangguth pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT clevin pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT oneth pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT jpeake pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT cerutten pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT ashcherbina pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT tktarrant pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT mgvossen pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT cawysocki pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT abelschner pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT dcadavid pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT yhu pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT hjiang pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT rmacleod pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT wtang pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT mtillinger pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension AT jdonadieu pb19384whimevaluatingmavorixaforanoralcxcr4antagonistinpatientswithwhimsyndromeviaaglobalphase3randomizedplacebocontrolledtrialwithopenlabelextension |